Zhejiang Shouxiangu Pharmaceutical Co Ltd: A Snapshot of Recent Performance and Operations

Zhejiang Shouxiangu Pharmaceutical Co., Ltd., a prominent player in the consumer staples sector, specializes in the manufacture and distribution of pharmaceutical products. Based in Jinhua, China, the company is known for its diverse product range, including dendrobium, ganoderma lucidum, and saffron. Beyond product manufacturing, Zhejiang Shouxiangu extends its expertise to offering edible fungus cultivation technology training and medical research services.

Stock Market Performance

As of May 15, 2025, the company’s stock closed at 21.23 CNH on the Shanghai Stock Exchange. This figure reflects a notable fluctuation over the past year, with the stock reaching a 52-week high of 28.45 CNH on May 20, 2024, and a low of 18.22 CNH on April 8, 2025. The market capitalization of Zhejiang Shouxiangu stands at 4.2 billion CNH, with a price-to-earnings ratio of 27.01, indicating investor sentiment and market valuation.

Business Operations and Offerings

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. is dedicated to the production of high-quality pharmaceutical products. The company’s portfolio includes well-regarded items such as dendrobium, known for its health benefits, ganoderma lucidum, a type of medicinal mushroom, and saffron, valued for its culinary and therapeutic properties. In addition to these products, the company is actively involved in the cultivation of edible fungi, providing training and technology support to enhance industry standards.

The company also engages in medical research, contributing to advancements in pharmaceutical sciences. This dual focus on production and research underscores Zhejiang Shouxiangu’s commitment to innovation and quality in the personal care products industry.

Further Information

For more detailed information about Zhejiang Shouxiangu Pharmaceutical Co., Ltd., including their product offerings and services, interested parties can visit their official website at www.sxg1909.com . The company continues to be a significant entity on the Shanghai Stock Exchange, reflecting its ongoing influence and presence in the pharmaceutical sector.